Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Bo Xu, Shaoqian Li, Bo-Kyeong Kang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 116

Showing 26-50 of 116 citing articles:

Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes
Mustafa Tanrıverdi, Mehmet Bastemır, Hadiye Demirbakan, et al.
BMC Endocrine Disorders (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Dapagliflozin promotes white adipose tissue browning though regulating angiogenesis in high fat induced obese mice
Lin Xiang, Min Liu, Guangda Xiang, et al.
BMC Pharmacology and Toxicology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
Empagliflozin alleviates neuroinflammation by inhibiting astrocyte activation in the brain and regulating gut microbiota of high-fat diet mice
Qiaoyan Huang, Liu Liu, Xiaoyao Tan, et al.
Journal of Affective Disorders (2024) Vol. 360, pp. 229-241
Closed Access | Times Cited: 4
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6300-6314
Open Access | Times Cited: 4
Unlocking the therapeutic potential of canagliflozin in NAFLD: Insights into AMPK/SIRT1-mediated lipophagy
Nahla E. El‐Ashmawy, Ghada M. Al‐Ashmawy, Asmaa A. Kamel, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 3, pp. 167666-167666
Closed Access
A comprehensive review of the efficacy and safety of ertugliflozin
Bo Xu, Yilin Liu, Tianqiao Zhang, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025)
Closed Access
Role of anti-diabetic medications in the management of MASLD
Scott Isaacs, Fiona V Farrelly, Paul Brennan
Frontline Gastroenterology (2025), pp. flgastro-102856
Closed Access
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors as a Dual Therapeutic Target for Cardiovascular and Renal Health: A Narrative Review
Sulthan Al Rashid, Inamul Hasan Madar, Iffath Misbah, et al.
Ibnosina Journal of Medicine and Biomedical Sciences (2025)
Open Access
Sodium–Glucose Cotransporter 2 Inhibitors as Potential Antioxidant Therapeutic Agents in Cardiovascular and Renal Diseases
Tapan Patel, Hong Zheng, Kaushik P. Patel
Antioxidants (2025) Vol. 14, Iss. 3, pp. 336-336
Open Access
The effect of empagliflozin and sitagliptin as an add-on therapy to metformin in blood pressure reduction in diabetic patients in primary health care settings in Riyadh, Saudi Arabia
Mayada Ahmed, Mohammed Altoyan, Raghad Hijazi, et al.
Journal of Family Medicine and Primary Care (2025) Vol. 14, Iss. 3, pp. 1116-1121
Open Access
Antifibrotic Therapies for Metabolic Dysfunction-associated Steatotic Liver Disease
Robert F. Schwabe, Frank Tacke, Atsushi Sugimoto, et al.
JHEP Reports (2025), pp. 101421-101421
Open Access
Risk of acute kidney injury in dapagliflozin users with type 2 diabetes: A nationwide propensity score‐matched cohort study in Korea
Hee‐Jin Kim, Heehyun Won, Suvin Park, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Open Access
Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment
Barbara Gieroba, Adrianna Kryska, Anna Sroka‐Bartnicka
Biochemistry and Biophysics Reports (2025) Vol. 42, pp. 102037-102037
Closed Access
Therapeutic application of natural compounds for skeletal muscle-associated metabolic disorders: A review on diabetes perspective
Khurshid Ahmad, Sibhghatulla Shaikh, Jeong Ho Lim, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115642-115642
Open Access | Times Cited: 10
GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
Alessio Mazzieri, Giuseppe Basta, Riccardo Calafiore, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis
Qing Zhang, Zhiwen Deng, Tudi Li, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 10
Open Access | Times Cited: 3
Association of sodium-glucose cotransporter 2 inhibitors with the incidence of corneal diseases in type 2 diabetes mellitus
Tsan-Yu Tsai, Po‐Jen Yang, Shih-Chun Chao, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 3, pp. 583-592
Open Access | Times Cited: 3
Canagliflozin protects against hyperglycemia-induced cerebrovascular injury by preventing blood-brain barrier (BBB) disruption via AMPK/Sp1/adenosine A2A receptor
Zhiyi Liu, Hua Wei, Sinan Jin, et al.
European Journal of Pharmacology (2024) Vol. 968, pp. 176381-176381
Closed Access | Times Cited: 3
Dapagliflozin increased pancreatic beta cell proliferation and insulinogenic index in mice fed a high-fat and high-sodium chloride diet
Tomonori Hirose, Hiroshi Takagi, Mitsuhiro Kuno, et al.
Biochemical and Biophysical Research Communications (2025) Vol. 749, pp. 151364-151364
Closed Access
Assessment of Antihyperglycemic and Modulatory Effects of trans‐Ferulic Acid on Glibenclamide and Metformin: In Vivo and Molecular Docking Studies
Md. Sakib Al Hasan, Md. Shimul Bhuia, Salehin Sheikh, et al.
ChemistrySelect (2025) Vol. 10, Iss. 14
Closed Access
Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis
Jie Ren, Shuhui Yang, Yifei Wang, et al.
British Journal of Clinical Pharmacology (2025)
Closed Access
Effects of empagliflozin and dapagliflozin, SGLT2 inhibitors, on miRNA expressions in diabetes-related cardiovascular damage in rats
H. Kiyak-Kırmacı, Ayşe Nur Hazar-Yavuz, Elif Beyzanur Polat, et al.
Journal of Diabetes and its Complications (2025) Vol. 39, Iss. 7, pp. 109063-109063
Closed Access
Mechanistic insights into the beneficial effects of curcumin on insulin resistance: Opportunities and challenges
Pitchai Balakumar, Kumar Venkatesan, Noohu Abdulla Khan, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103627-103627
Closed Access | Times Cited: 9
Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels
Anxiang Cai, Jianxiao Shen, Xiaoqian Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 11, pp. 465-465
Open Access | Times Cited: 9

Scroll to top